|
Number of patients
|
102
|
|
Observation period, days, median [range]
|
733 [153–3278]
|
|
Age, years, median [range]
|
69 [34–89]
|
|
Sex (men), n (%)
|
70 (68.6)
|
|
BMI in men, kg/m2, median [range]
|
23.5 [16.2–33.8]
|
|
BMI in women, kg/m2, median [range]
|
23.0 [16.0–37.5]
|
|
Baseline L3 SMI in men, cm2/m2, median [range]
|
47.1 [31.5–64.4]
|
|
Baseline L3 SMI in women, cm2/m2, median [range]
|
36.5 [25.6–55.6]
|
|
Etiology, n (%)
|
|
HBV
|
11 (10.8)
|
|
HCV
|
50 (49.0)
|
|
NBNC
|
41 (40.2)
|
|
Alcohol
|
26 (25.5)
|
|
NASH
|
7 (6.9)
|
|
PBC
|
2 (2.0)
|
|
Cryptogenic
|
6 (5.9)
|
|
ALT, U/L, median [range]
|
37 [9–243]
|
|
Total bilirubin, mg/dL, median [range]
|
1.0 [0.4–3.5]
|
|
Albumin, g/dL, median [range]
|
3.7 [2.0–4.9]
|
|
Platelet count, × 104/μL, median [range]
|
12.1 [2.2–80.9]
|
|
Child-Pugh classification (A/B/C), n (%)
|
68(66.7)/34(33.3)/0(0)
|
|
AFP, ng/mL, median [range]
|
21.8 [1.0–633,900]
|
|
TNM stage (I/II/III/IV), n (%)
|
11(10.8)/22(21.6)/46(45.1)/23(22.5)
|
|
Maximum tumor diameter, mm, median [range]
|
32 [9–198]
|
|
Number of tumors (solitary/multiple), n (%)
|
29(28.4)/73(71.6)
|
|
Treatment sessions between CT exams, sessions, median [range]
|
1 (1–6)
|
|
Treatment modality (TACE/TAI/TACE+TAI), n (%)
|
18(17.6)/25(24.5)/59(57.8)
|
|
mRECIST assessment (CR/PR/SD/PD), n (%)
|
18(17.6)/26(25.5)/9(8.8)/49(48.0)
|
|
BCAA supplementation (presence/absence), n (%)
|
72(70.6)/30(29.4)
|
|
Cause of death (liver-related/infection/GI bleeding/others/unknown), n
|
57/7/2/4/2
|
